Member Info for AquaeSulis01

Zenakine™ is a cutting-edge neuroactive ingredient designed to counteract the effects of stress on the skin and improve overall wellbeing. It works in sync with the skin’s natural biological rhythms, enhancing melatonin production to help improve sleep quality, elevating positive emotions and stimulating skin regeneration. It is the first ingredient with clinical instrumental measures on sleep quality and duration benefits

INCI name

Lactobacillus Ferment Lysate (and) Glycerin (and) Pentylene Glycol (and) Propanediol (and) Xanthan Gum

Looking good

Zenakine is now listed on Croda's website as an ingredient used in; Clinical Studies Night Cream, Bioferment-Infused Reviving Cream, Harmonising Beauty Mist, and Timeless Sleeping Mask

https://www.crodabeauty.com/en-gb/formulations/formulation/6490-conditioningpowder

Thanks elrico. Boots seems like a VIP to us because it primarily operates in the UK; other Countries are restricted to Ireland, Italy, Norway, the Netherlands, Thailand and Indonesia so can understand why it wouldn't make Croda's top 12 list

As soon as SA has something worth communicating he is obliged to "sharing the marketing information with shareholders upon its official launch in April. ". We should know by close of play 8th Apr whether Zenakine has won the In-Cosmetic award for which it is one of 11 ingredients shortlisted.

Back to the subject heading. I have done some further digging into the Boots Future No7 range and its upcoming launch with new ingredients. The link with Manchester University is to do with their "pepticology" (blend of different peptides. However, it is worth noting one of the key peptides in the current blend is Matrixyl 3000+ (link 1 =) and if we are right about skinbiotix replacing matrixyl then the claim from a reviewer that the upcoming launch does not contain a "retinol" but achieves the same benefits (link 2) then every chance it is skinbiotix "What does No7 Future Renew do?

In short, Future Renew promises to reverse the signs of skin damage—and it's proven to do it. Up until now, it's been more or less thought that without the help of a retinoic acid, the signs of skin damage (such as, fine lines, wrinkles, lack of luminosity, dryness, uneven skin tone and loss of firmness) have been more or less impossible to reverse. But Future Renew promises to do it without a retinoid, meaning it's highly tolerable for all skin types, while also being highly potent."

https://www.no7beauty.co.uk/skincare-ingredient-peptides.list?srsltid=AfmBOoqFxP8h3x2zfENFMvjWRG_Q2PzQ3sLLvobzKD_oj3tG6lu1kemX

https://www.marieclaire.co.uk/beauty/skincare/no7-future-renew

You need to check your facts net

"Sederma

Sederma is the inventor, and only supplier, of the Matrixyl® range of products, and is part of Croda International Plc."

https://www.matrixylinside.com/en-gb

Suspect you are getting confused with retinol

Net, now that you have moved on from:

"pglancy: i think you need to read my 'back of a *** packet' post again. "if" croda can work out their "rough and ready" share by product sold then so can sbtx.....

boots will be working on a 50% gross margin.... its possible (but unlikely) that the main cost are the ingredients..... but suppose they its only 50% of the cost.

then if boots sell 1m £30 products at 50% markup means the original cost was £20m .

assume ingredients only half the costs. that means £10m goes to croda and £1m to sbtx.

20 boots type deals for croda gives sbtx (at 10%) £20m profit.

cheers net."

To your ingredient only focus speculation, the answer is your guess is as good as any

Net, if Boots and others sold say matrixyl as an end product you would be correct but they don't, it is an ingredient costing x within a product costing y so using y sales at a product sales price as a basis for calculating the percentage is flawed because the concentration of matrixyl and hence its part of the product price will vary product by product. In the attached example matrixyl makes up just 10% of the ingredients in the boots No7 productbut that might represent 30% or just 3% of the overall cost of the product, we just don't know.

https://www.boots.com/the-ordinary-matrixyl-ha-30ml-10286190?srsltid=AfmBOorwDB4m8mSMPnZHMR3HKH_4_OlLxyxrUb6HdwFhL9KBej9bKToZ

Think you're getting confused with Opti Leapfroggy

"The terms are based on the original agreement with SkinBioTherapeutics being paid tiered royalties based on global sales revenues on any licensed products derived from the partnership." so volume will dictate the double digit percentage

Too much of a coincidence? https://www.boots.com/no7/future-renew

Interesting article about the shift in the anti-aging focus which demonstrates why skinbiotix is the right product at the right time

https://www.cosmeticsdesign-europe.com/Article/2025/03/14/anti-aging-reimagined/

Croda's section has been updated.

https://www.crodabeauty.com/en-gb/stay-connected/incos-2025-landing-page?utm_source=cosmetics+business+magazine&utm_medium=email&utm_campaign=email_beauty_english_global_brand+awareness_2025-03-19_emea+beauty+incos+2025+preview_0_0_0_0_0_0_0_0_0&sc_camp=E2B7402184DC45DFF2B1F6AA0C039BC2

What's new on stand?

At this year’s in-cosmetics, we will be focusing on our innovative technologies across a broad range of personal care applications and also includes the launch of three brand new ingredients for hair care, actives, and botanicals that will be unveiled on stand on April 8.

Technical seminar

Join Dr Alba Cico, Research Team Leader, and Hishda Mohamed, Technical Marketing Coordinator from our Croda Beauty Actives team who will be delivering a technical seminar on Tuesday 8 April in Technical Seminar Theatre 4, Hall 13 from 10:45 – 11:15. Their seminar will focus of reducing premature ageing by improving emotional resilience, introducing breakthrough active cosmetic ingredient to reduce psychological stress. Click HERE for more information.

No reason why the ingredients can't complement one another

https://www.medik8.com/pages/how-do-peptides-and-ceramides-compare-to-each-other#:~:text=Ceramides%20strengthen%20the%20skin%20barrier,elastin%20for%20repair%20and%20renewal.

No net, they are lipids (fatty acids) whilst skinbiotix is a peptide

The part of the paid for Edison Report i homed in on was "Financials: No more equity at parent company level

As is typical for exploration companies, KEFI has funded its pre-development activities with regular equity raising. It had £2.0m in net debt on its balance sheet as at 30 June 2024 (cf £1.9m as at 31 December 2023), after £5.9m in operating and investing cash outflows before working capital and after having raised £2.3m (net) in equity over the prior six months. In H2, we estimate that it raised a net £8.8m in equity, followed by a further £4.9m in early FY25, such that we do not now anticipate any further dilutive equity issues at parent company level in the foreseeable future. Companies on the verge of closing large project financing often have small working capital facilities offered to them as bridging finance support. If this is applied to KEFI, as long as it is neither large nor dilutive, any impact on our valuations will be immaterial owing to KEFI’s now solidifying non-dilutive plans for project financing the development capital. Hereafter, financing of the project’s funding requirement of US$320m is assumed to be via US$240m in senior debt, US$20m in Ethiopian government participation at project level and US$60m in US dollar-linked preference shares. As a result, KEFI will be developing Tulu Kapi from a relatively small equity capital base, albeit the potential GMCO sale proceeds will provide a buffer as well as a source of growth capital."

So no more placings needed, now just a short term waiting game, happy days

Sederma = Croda Beauty Actives "In 1993, Croda Beauty actives (then known as Sederma) produced the first characterised peptides for cosmetic application. Since then, our peptides, particularly Matrixyl, have been the industry standard for anti-ageing active ingredients and one of the rare ingredient names that is recognised by consumers. Matrixyl is often used as a benchmark to evaluate the anti-wrinkle capabilities of other anti-ageing active ingredients and holds the 25 Years of Innovation award to reflect its unrivalled impact on the beauty ingredients market.

Today, over 1500 products across the globe include Matrixyl in their skin care formulas."

https://www.crodabeauty.com/en-gb/capabilities/actives

Croda have of course been careful to preserve the Sederma name since it took it over in 1997, and so technically correct to refer to beauty active clients as Sederma clients as accurately describes the segment of the Croda Group market that skinbiotix is targeted at.

Regarding "dirty product transition", skinbiotix falls under the peptide category and Croda have already announced they intend to transition across to PFAS free peptides by 2026.

https://www.cosmeticsandtoiletries.com/cosmetic-ingredients/actives/news/22930378/croda-croda-beauty-highlights-pfasfree-peptides-commits-to-complete-portfolio-transition-by-2026

"And SA has never publicly stated that the payment did arrive." technically true although SA at the Dec Inv Meets circa 11 mins in did state Croda confirmed he would still be receiving payment by Calendar Year End. Now if I was Croda and SA, bearing in mind the scrutiny taking place by Investors to identify the Croda Initial Revenue in advance of the launch I would arrange for payment to arrive 02nd Jan 2025

I know Toyin and share your frustration but guess my expectations for the Interims weren't great in the first place. Most disappointing thing for me was no noticeable uplift from the Umesh Modi Pheet Heel Balm launch looking at the figures for Dermatonics and the fact that the small uplift shown was put down to Amazon and the USA " Dermatonics revenues increased by 14% to £1.03m (HY24: £0.91m) due to expansion in Amazon orders in the UK and USA"

Blimey, an unhappy Toyin, elric must be earning his subscription fee right now :)

The FY results had the reassuring statement that " Post acquisitions, annualised Group turnover for FY25 expected to be £6.3m; post Croda agreement, Directors anticipate the Group will be cash flow positive from FY25 on an annual basis, with no further need to seek additional funds for working capital" and people are trying to work out whether the Interim statement "Following the completion of the second acquisition, BTS, during H1 25, the Group is in a much stronger financial and operational position, creating a platform to reach profitability in the medium term. " still means this is the case. Of course the joker in the pack is the Croda revenue; how much and how soon so any sales I suspect will be temporary and buyers will return as the launch approaches, takes place, and it becomes clearer how big a financial impact it will make to SBTX